Latest News - Danaher
Top Corporates Hub
Danaher
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
24.07.2026 12:54
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
The 'Standout Performance' That Could Save Thermo Fisher, Danaher And Others
23.07.2026 13:42
Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.
Danaher (DHR) Q2 2026 Earnings Call Transcript
22.07.2026 00:30
Non-respiratory growth accelerated 150 basis points as life sciences recovered.
Stocks Rise Pre-Bell as Investors Await More Earnings, Monitor Middle East Developments
21.07.2026 11:48
US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora
Danaher shares slide despite second-quarter earnings and revenue beat (DHR)
21.07.2026 11:16
Strong quarterly performance overshadowed by softer near-term outlookDanaher Corporation (NYSE:DHR) reported second-quarter results that exceeded Wall Street expectations, but investors focused on a more cautious growth outlook for the current quarter, sending the shares down 9% in pre-market trading. The life sciences and diagnostics company posted adjusted earnings per share of $1.
Tech Rebound Boosts Wall Street Pre-Bell; Asia, Europe Up
21.07.2026 11:10
Wall Street futures pointed higher pre-bell Tuesday as tech traders toggled risk-on switches despite
Danaher shares tumble despite earnings beat
21.07.2026 10:49
Investing.com -- Danaher Corporation (NYSE:DHR) reported second quarter results that exceeded analyst expectations, but shares fell 9% premarket.
Danaher (NYSE:DHR) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops
21.07.2026 10:23
Diversified science and technology company Danaher (NYSE:DHR) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.5% year on year to $6.27 billion. Its non-GAAP profit of $1.94 per share was 4.9% above analysts’ consensus estimates.
Danaher Reports Second Quarter 2026 Results
21.07.2026 10:00
Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Danaher Corporation 2026 Q2 - Results - Earnings Call Presentation
21.07.2026 08:30
2026-07-21. The following slide deck was published by Danaher Corporation in conjunction with their 2026 Q2 earnings call.
Danaher (DHR) Q2 Earnings Report Preview: What To Look For
20.07.2026 05:09
Diversified science and technology company Danaher (NYSE:DHR) will be reporting results this Tuesday before market hours. Here’s what you need to know.
Danaher (DHR) Stock May Trade At A Discount Despite Its 18% Five Year Decline
17.07.2026 05:09
Danaher stock presents a clear valuation tension right now, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while the earnings based multiples suggest the shares are already pricing in a premium. Over the past 5 years, Danaher shareholders have seen the stock decline about 18%, which frames the current valuation debate against a weaker long term return profile. Recent news around portfolio moves in diagnostics and pathology can support expectations...
Can Masimo’s Integration and Bioprocessing Strength Reshape Danaher’s Long-Term Story (DHR)?
17.07.2026 02:14
Danaher, which released its Q2 2026 results on 21 July, saw expectations firm up ahead of the report as analysts projected modest year-on-year growth in revenue and earnings, helped by solid bioprocessing demand, improved filtration activity, and contributions from the Masimo acquisition despite cost pressures and higher debt. Investors are focusing on how Masimo’s integration and continued strength in bioprocessing and diagnostics could offset weaker areas like Diagnostics and rising input,...
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
16.07.2026 13:15
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
14.07.2026 14:00
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cell Isolation Market/Cell Separation Market by Product, Cell Type, Source, Technique, Application, End User, Competition, Region - Global Forecast to 2031
13.07.2026 08:31
The cell isolation market is projected to grow from USD 4.39 billion in 2026 to USD 7.97 billion by 2031, with a CAGR of 12.7%. Key drivers include the expansion of cell and gene therapy, rising demand for immune cell isolation, and increased adoption of automated systems. Techniques like centrifugation, magnetic and fluorescence-activated cell sorting, and microfluidics enable enrichment of immune, stem, and tumor cells. The consumables segment is set to lead growth, propelled by the recurring
Jim Cramer on Danaher: “I Don’t Want You Anywhere Near That One”
10.07.2026 12:01
Danaher Corporation (NYSE:DHR) was among the stocks Jim Cramer discussed during Mad Money, as he called the growing wave of stock offerings and debt issuance a threat to the bull market. Expressing their wish to diversify, a caller inquired about the stock, and Cramer commented: Danaher’s been a huge disappointment, and we managed to get […]
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
10.07.2026 09:26
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
Beckman Coulter Diagnostics Expands Alzheimer's Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay
07.07.2026 07:00
Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer's Association International Conference (AAIC) 2026 in London.
Evercore ISI Group Maintains Outperform on Danaher, Lowers Price Target to $230
06.07.2026 12:08
Evercore ISI Group analyst Vijay Kumar maintains Danaher (NYSE:DHR) with a Outperform and lowers the price target from $232 to $230.